"Engineering Adipose Tissue Organoids For Developing Novel Therapeutics"


The ADIPOTECH project (2025 - 2028) aims to develop physiologically relevant 3D adipose tissue organoids that overcome the limitations of traditional 2D models, thereby improving preclinical predictability and translation to clinical outcomes.

The ADIPOTECH team is developing advanced 3D co-culture systems to recreate the complex cellular environment of human adipose tissue (AT). The project combines adipocytes with immune cells, endothelial cells, and neurons to model key interactions that drive AT function and dysfunction in metabolic disease. Using stepwise work packages, the team will first establish adipocyte–immune, adipocyte–endothelial, and adipocyte–neuron co-cultures, before integrating all cell types into a single multi-cellular 3D model. This will result in the first comprehensive in vitro model of human AT, enabling mechanistic studies and drug discovery targeting AT inflammation, vascular and neural regulation, and cardiometabolic disorders such as obesity, type 2 diabetes, and atherosclerosis.


THE ADIPOTECH TEAM


Academic team members

Zach Gerhart-HinesAssociate Professor, University of Copenhagen

  • Head of ADIPOTECH
  • Adipose tissue metabolism, genetic manipulation, and fat-nerve interactions

Carolina Hagberg, Associate Professor, Karolinska Institutet

  • Vascularized adipose tissue organoids, and interaction between fat cells and blood vessels

Lucile Dollet, Assistant Professor, University of Copenhagen

  • Adipose tissue immunometabolism, immune signaling, and cell–cell communication in adipose tissue

Industrial team member

  • Thomas Åskov Pedersen, Senior Principal Scientist, Novo Nordisk

“This project is about closing the gap between basic biology and implementation in research and development. With ADIPOTECH, we’re building a model that researchers and companies alike can use to develop better, more targeted treatments,”

Zachary Gerhart-Hines, Head of the ADIPOTECH project


“We’re engineering organoid models that reflect the real cellular complexity of adipose tissue. The goal is to provide a tool that brings us closer to understanding - and treating - metabolic disease,”

Carolina Hagberg, principal investigator in ADIPOTECH

“Recently there has been an explosion of data on disease genetics and (adipose) tissue composition and gene/protein expression at single-cell resolution. As an industrial partner in this collaboration, we are excited for the opportunity to co-develop cellular models that will enable us to harvest this novel data, test new hypotheses, and funnel the knowledge into projects leading to the development of treatments for cardiometabolic diseases”

Thomas Åskov Pedersen, company partner from Novo Nordisk.


ABOUT ODIN

We unite bright minds from industry and academia to jointly create need-driven clinical research projects - and pave the way for innovative new treatments and diagnostics. We fund the best project ideas through competitive funding calls. Although companies cannot receive funding, it is free of charge to join.

The platform is sponsored by the Novo Nordisk Foundation with 180 million DKK from 2024-2029.

CONTACT ODIN

You are welcome to contact us if you have questions or comments. Reach out to odin@au.dk or find the Secretariat's direct email addresses under contacts.

Although the platform spans five Danish universities, we're based in Aarhus. Our office is located at Aarhus University, Ny Munkegade 116, Bldg 1535-117.